Vilobelimab

About InflaRx

InflaRx is a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics targeting the C5a/C5aR pathway of the complement system. Its most significant achievement is the FDA Emergency Use Authorization for vilobelimab (GOHIBIC) in critically ill COVID-19 patients. The company's strategy involves leveraging its selective C5a inhibition platform to address both acute, life-threatening conditions like ARDS and chronic inflammatory diseases such as pyoderma gangrenosum, though recent Phase 3 setbacks in the latter have refocused efforts on acute care and other indications.

About InflaRx

InflaRx is a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics targeting the C5a/C5aR pathway of the complement system. Its most significant achievement is the FDA Emergency Use Authorization for vilobelimab (GOHIBIC) in critically ill COVID-19 patients. The company's strategy involves leveraging its selective C5a inhibition platform to address both acute, life-threatening conditions like ARDS and chronic inflammatory diseases such as pyoderma gangrenosum, though recent Phase 3 setbacks in the latter have refocused efforts on acute care and other indications.

Therapeutic Areas